Platelet-derived CD40L: The switch-hitting player of cardiovascular disease

Circulation

Volumn 106, Issue 8, 2002, Pages 896-899

  André, Patrick ^a   Nannizzi Alaimo, Lisa ^a   Prasad, Srinivasa K ^a   Phillips, David R ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Cardiovascular diseases; Editorials; Glycoproteins; Platelets; Restenosis

Indexed keywords

C REACTIVE PROTEIN; CD40 LIGAND; CHOLESTEROL; LOW DENSITY LIPOPROTEIN; TUMOR NECROSIS FACTOR;

ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CELL INTERACTION; EDITORIAL; HUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RESTENOSIS; THROMBOCYTE AGGREGATION;

ARTERIOSCLEROSIS; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; CD40 LIGAND; CELL MOVEMENT; ENDOTHELIUM, VASCULAR; GRAFT OCCLUSION, VASCULAR; HUMANS; INFLAMMATION MEDIATORS; MODELS, CARDIOVASCULAR;

EID: 0037143597     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000028962.04520.01     Document Type: Editorial

References (22)

1. CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species
2. The CD40/CD154 receptor/ligand dyad
3. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells
4. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40
5. CD40L stabilizes arterial thrombi by a beta-3 integrin-dependent mechanism
6. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina: Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes
7. Reduction of atherosclerosis in mice by inhibition of CD40 signalling
8. Requirement for CD154 in the progression of atherosclerosis
9. The pathogenesis of atherosclerosis-an update
10. Resistance to atherosclerosis in pigs with von Willebrand's disease
11. Cardiopulmonary bypass induces the release of soluble CD40L
12. Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets
13. Platelets and cytokines in concert with endothelial activation in patients with peripheral arterial occlusive disease
14. Soluble CD40L and cardiovascular risk in women
15. Platelet derived CD154 (CD40 ligand) and febrile responses to transfusion
16. GP IIb-IIIa antagonists demonstrate a dose-dependent inhibition and potentiation of soluble CD40L (CD154) release during platelet stimulation
17. In vivo transfer of human hepatocyte growth factor gene accelerates re-endothelialization and inhibits neointimal formation after balloon injury in rat model
18. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta-3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication
19. Eptifibatide in percutaneous coronary intervention: The ESPRIT trial results
20. Soluble CD154 in rheumatoid arthritis: Elevated plasma levels in cases with vasculitis
21. Elevation and biological activity of CD40 ligand (CD40L): Potential mechanism of platelet-mediated inflammation in sickle cell disease
22. The soluble CD40 ligand sCD154 in systemic lupus erythematosus